AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23748750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23748750 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (0.25 mg bid on day 6 and 0.25 mg qd on days 7-14)
Number of subjects: 20
Study 23748750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and digoxin co-administration
Number of subjects: 20
Study 20965379 — intervention group
Group type: EXPERIMENTAL
Intervention: New Moves intervention (all-girls physical education class, nutrition and self-empowerment components, motivational interviewing, lunch meetings, parent outreach)
Number of subjects: 356
Study 20965379 — intervention group
Group type: EXPERIMENTAL
Intervention: New Moves intervention
Number of subjects: 356
Study 20965379 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 356
Study 19099634 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose thalidomide (HD-T)
Number of subjects: 85
Study 19099634 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide + VAD chemotherapy (T-VAD)
Number of subjects: 85
Study 19099634 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide + MP chemotherapy (T-MP)
Number of subjects: 85
Study 19099634 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide + dexamethasone (TD)
Number of subjects: 85
Study 19099634 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose thalidomide (LD-T)
Number of subjects: 85
Study 19099634 — intervention group
Group type: COMPARATOR
Intervention: Conventional VAD chemotherapy
Number of subjects: 85
Study 19099634 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions in 5 groups
Number of subjects: 85
Study 19099634 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related mortality
Number of subjects: 85
Study 19099634 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of TNF-alpha in ineffective group
Number of subjects: 85
Study 19099634 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of TNF-alpha in effective group
Number of subjects: 85
Study 15119586 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion alone
Number of subjects: 90
Study 15119586 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis followed by acid etching
Number of subjects: 90
Study 15119586 — intervention group
Group type: COMPARATOR
Intervention: Mechanical widening with bur and etching
Number of subjects: 90
Study 15119586 — intervention group
Group type: COMPARATOR
Intervention: Air abrasion and etching
Number of subjects: 90
Study 11413082 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferral of PTCA
Number of subjects: 325
Study 11413082 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance of PTCA
Number of subjects: 325
Study 11413082 — intervention group
Group type: COMPARATOR
Intervention: Reference group (PTCA performed as planned)
Number of subjects: 325
Study 9595974 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg daily for 2 consecutive days every month for 6 months
Number of subjects: 26
Study 9595974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9595974 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG treatment
Number of subjects: 26
Study 8015122 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate method for generating a sequence of random numbers
Number of subjects: 206
Study 8015122 — intervention group
Group type: EXPERIMENTAL
Intervention: Concealment of assignment until treatment allocation
Number of subjects: 206
Study 8015122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sequence generation and allocation concealment
Number of subjects: 206
Study 8015122 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted randomization
Number of subjects: 206
Study 8015122 — intervention group
Group type: COMPARATOR
Intervention: Hypothesis tests for baseline characteristics
Number of subjects: 206
Study 3220231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal lipase (FL) (Rhizopus arrhizus)
Number of subjects: 13
Study 3220231 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical porcine pancreatic extract (Eurobiol)
Number of subjects: 13
Study 3220231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29550783 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month targeted exercise training programme
Number of subjects: 0
Study 29550783 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month cognitive and social enrichment programme
Number of subjects: 0
Study 29550783 — intervention group
Group type: COMPARATOR
Intervention: 6-month stretch and tone programme (control)
Number of subjects: 0
Study 27444251 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 27444251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24687830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 1194
Study 24687830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1194
Study 21992867 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene wrap with previous drying
Number of subjects: 0
Study 21992867 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene wrap without previous drying
Number of subjects: 0
Study 21992867 — intervention group
Group type: COMPARATOR
Intervention: Sterile preheated field (Control)
Number of subjects: 0
Study 20399512 — intervention group
Group type: EXPERIMENTAL
Intervention: +3953TT in IL1B
Number of subjects: 296
Study 20399512 — intervention group
Group type: EXPERIMENTAL
Intervention: ‐592C/A heterozygosity in IL10
Number of subjects: 296
Study 20399512 — intervention group
Group type: EXPERIMENTAL
Intervention: Other polymorphisms
Number of subjects: 296
Study 20399512 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNGR1 818del4 mutation
Number of subjects: 296
Study 17917909 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective picture version
Number of subjects: 60
Study 17917909 — intervention group
Group type: COMPARATOR
Intervention: Objective picture version
Number of subjects: 60
Study 17917909 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective representations
Number of subjects: 60
Study 17917909 — intervention group
Group type: COMPARATOR
Intervention: Objective representations
Number of subjects: 60
Study 15863678 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodological quality assessed using the Jadad score
Number of subjects: 231
Study 15863678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical quality assessed using the Berdeu score
Number of subjects: 231
Study 15863678 — intervention group
Group type: EXPERIMENTAL
Intervention: Year of commencement of trials
Number of subjects: 231
Study 15863678 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between methodological quality and number of participating patients
Number of subjects: 231
Study 15863678 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between ethical quality and number of participating patients
Number of subjects: 231
Study 15863678 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between ethical quality and methodological quality
Number of subjects: 231
Study 15863678 — intervention group
Group type: EXPERIMENTAL
Intervention: Obtaining ICP and REC approval
Number of subjects: 231
Study 11157566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sporadic Parkinson's disease
Number of subjects: 24
Study 11157566 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial Parkinson's disease
Number of subjects: 24
Study 11157566 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 9536525 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 0
Study 9536525 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 0
Study 7949271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Education (IE)
Number of subjects: 104
Study 7949271 — intervention group
Group type: COMPARATOR
Intervention: Usual Education (UE)
Number of subjects: 104
Study 2853751 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine infusion (3 micrograms/kg per min) during glucose infusion (20 min) in group I
Number of subjects: 16
Study 2853751 — intervention group
Group type: COMPARATOR
Intervention: Atenolol infusion (1 micrograms/kg per min) in group II
Number of subjects: 16
Study 31339533 — intervention group
Group type: COMPARATOR
Intervention: Combat Application Tourniquet (CAT)
Number of subjects: 102
Study 31339533 — intervention group
Group type: COMPARATOR
Intervention: Special Operation Forces Tactical Tourniquet
Number of subjects: 102
Study 31339533 — intervention group
Group type: COMPARATOR
Intervention: Stretch‐Wrap‐and‐Tuck Tourniquet
Number of subjects: 102
Study 31339533 — intervention group
Group type: COMPARATOR
Intervention: Rapid Application Tourniquet System
Number of subjects: 102
Study 31339533 — intervention group
Group type: COMPARATOR
Intervention: Improvised tourniquet
Number of subjects: 102
Study 27943089 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem co-treatment with microemulsified cyclosporine-A (CsA)
Number of subjects: 39
Study 27943089 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without diltiazem)
Number of subjects: 39
Study 25278482 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity ischemia
Number of subjects: 40
Study 25278482 — intervention group
Group type: COMPARATOR
Intervention: Lower extremity ischemia
Number of subjects: 40
Study 24761498 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex agglutination test
Number of subjects: 80
Study 22257497 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐adjuvanted whole‐virion H1N1 influenza vaccine
Number of subjects: 318
Study 22257497 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03B‐adjuvanted split‐virion H1N1 influenza vaccine
Number of subjects: 318
Study 22257497 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent seasonal influenza vaccine
Number of subjects: 318
Study 19405858 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential laser therapy using two identical laser probes (810 nm, 100 mW, 15 sessions, 6 J/point)
Number of subjects: 152
Study 19405858 — intervention group
Group type: COMPARATOR
Intervention: Conventional laser therapy with one live probe and one dummy probe (810 nm, 100 mW, 15 sessions, 6 J/point)
Number of subjects: 152
Study 16685050 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown diet (BD) rich in Maillard reaction products (MRPs)
Number of subjects: 18
Study 16685050 — intervention group
Group type: COMPARATOR
Intervention: White diet (WD) poor in Maillard reaction products (MRPs)
Number of subjects: 18
Study 15566392 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of triclabendazole for 1 day (single-dose)
Number of subjects: 165
Study 15566392 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of triclabendazole for 2 days (double-dose)
Number of subjects: 165
Study 15566392 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of triclabendazole for 3 days (triple-dose)
Number of subjects: 165
Study 15566392 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 165
Study 11780767 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography analyzed in conjunction with an artificial neural network (ANN) for breast cancer diagnosis.
Number of subjects: 0
Study 9413756 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nephrolithiasis
Number of subjects: 50
Study 9413756 — intervention group
Group type: COMPARATOR
Intervention: Non-active nephrolithiasis
Number of subjects: 50
Study 9413756 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 50
Study 8216115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine catheters with titrated oxytocin to achieve the 75th percentile of uterine activity
Number of subjects: 239
Study 8216115 — intervention group
Group type: COMPARATOR
Intervention: External tocography with titrated oxytocin to achieve 6 to 7 contractions per 15 minutes each lasting > 40 seconds
Number of subjects: 239
Study 31219175 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult Day Services (ADS) use (yes)
Number of subjects: 509
Study 31219175 — intervention group
Group type: COMPARATOR
Intervention: No Adult Day Services use (no)
Number of subjects: 509
Study 29996882 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiao-Chang Ke-Min (TCKM) granules
Number of subjects: 0
Study 29996882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26963615 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar RF‐based device for home use
Number of subjects: 50
Study 26963615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24211112 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated self-care intervention
Number of subjects: 71
Study 24211112 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study 22472791 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg antigen with a full (9.75 mg) adjuvant dose
Number of subjects: 423
Study 22472791 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 μg antigen with a half (4.875 mg) adjuvant dose
Number of subjects: 423
Study 22472791 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccine formulations
Number of subjects: 423
Study 20973714 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Monitoring (EM)
Number of subjects: 31
Study 20973714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill Counts
Number of subjects: 31
Study 20973714 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Medication Diary
Number of subjects: 31
Study 20973714 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Medication Diary
Number of subjects: 31
Study 20973714 — intervention group
Group type: EXPERIMENTAL
Intervention: EM Adherent Group
Number of subjects: 31
Study 20973714 — intervention group
Group type: EXPERIMENTAL
Intervention: EM Nonadherent Group
Number of subjects: 31
Study 18258801 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxemia (mean nadir Po(2) 5.8 +/- 0.5 kPa)
Number of subjects: 20
Study 18258801 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia (mean nadir plasma glucose 2.7 +/- 0.5 mmol/l)
Number of subjects: 20
Study 18258801 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemic normoxia (control)
Number of subjects: 20
Study 15930210 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DP) at doses of 2.5, 5, 7.5, or 10 microg/kg per minute; n = 28
Number of subjects: 59
Study 15930210 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (EP) at doses of 0.125, 0.250, 0.375, or 0.5 microg/kg per minute; n = 32
Number of subjects: 59
Study 12957457 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (4.5, 6.75, 9.0, 12.0, 13.5, and 15.0 microg/kg) administered every 3 weeks for 12 weeks
Number of subjects: 249
Study 12957457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 9888119 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture (Ac)
Number of subjects: 438
Study 9888119 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (sham Ac)
Number of subjects: 438
Study 9888119 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment without Ac
Number of subjects: 438
Study 9888119 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture (Ac) at three dose levels (28, 16, or 8 treatments)
Number of subjects: 438
Study 8894955 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive-behaviour therapy (CBT)
Number of subjects: 53
Study 8894955 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training (Control)
Number of subjects: 53
Study 1355426 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0
Study 1355426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 1355426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0
Study 1355426 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0
Study 6682336 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol (50 mg) alone
Number of subjects: 40
Study 6682336 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol (50 mg) and testosterone (100 mg)
Number of subjects: 40
Study 31662354 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-interventional studies
Number of subjects: 52
Study 31662354 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised trials
Number of subjects: 52
Study 31662354 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous reports
Number of subjects: 52
Study 31662354 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes to product information
Number of subjects: 52
Study 31662354 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketing authorisation withdrawal or suspension
Number of subjects: 52
Study 29901815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg every 4 weeks
Number of subjects: 2176
Study 29901815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 2 weeks
Number of subjects: 2176
Study 29901815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2176
Study 27367995 — intervention group
Group type: EXPERIMENTAL
Intervention: Public Reporting of Health Care Performance (PRHCP)
Number of subjects: 748632
Study 24945393 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal staples (Leukosan Skin Stapler)
Number of subjects: 72
Study 24945393 — intervention group
Group type: COMPARATOR
Intervention: Conventional continuous Donati suture
Number of subjects: 72
Study 24945393 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal staples
Number of subjects: 72
Study 22046977 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum interleukin-6 (IL-6) levels obtained 24-48 hours before delivery
Number of subjects: 39
Study 22046977 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum interleukin-6 (IL-6) levels obtained 48-72 hours before delivery
Number of subjects: 39
Study 22046977 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 level of 1.98 pg/ml
Number of subjects: 39
Study 19384220 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily bathing with chlorhexidine solution
Number of subjects: 0
Study 17082978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention for anger management (6 sessions of 2 hours each)
Number of subjects: 45
Study 17082978 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 45
Study 15345983 — intervention group
Group type: EXPERIMENTAL
Intervention: Less Invasive Stabilization System (L.I.S.S.) plating
Number of subjects: 38
Study 15345983 — intervention group
Group type: EXPERIMENTAL
Intervention: L.I.S.S plate
Number of subjects: 38
Study 15345983 — intervention group
Group type: COMPARATOR
Intervention: Standard double plate construct
Number of subjects: 38
Study 11583367 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosine 2 mg/day
Number of subjects: 91
Study 11583367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 11583367 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Terazosine and Placebo
Number of subjects: 91
Study 9555827 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Trauma Life Support (ATLS) training
Number of subjects: 88
Study 9555827 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Trauma Life Support (ATLS) audit
Number of subjects: 88
Study 9555827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ATLS training)
Number of subjects: 88
Study 7734784 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 926
Study 7734784 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary manipulation for the first 4 weeks of life
Number of subjects: 926
Study 2736104 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-differentiated tumour
Number of subjects: 276
Study 2736104 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary tumour
Number of subjects: 276
Study 2736104 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive tumour pattern
Number of subjects: 276
Study 2736104 — intervention group
Group type: COMPARATOR
Intervention: Non-aggressive tumour pattern
Number of subjects: 276
Study 1091993 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorised foot mover
Number of subjects: 0
Study 1091993 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic compression
Number of subjects: 0
Study 1091993 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin
Number of subjects: 0
Study 1091993 — intervention group
Group type: COMPARATOR
Intervention: Coumadin
Number of subjects: 0
Study 1091993 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 1091993 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 0
Study 1091993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran
Number of subjects: 0
Study 1091993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium pentosan polysulphate
Number of subjects: 0
Study 31953482 — intervention group
Group type: EXPERIMENTAL
Intervention: RC14-GR1
Number of subjects: 207
Study 31953482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 31953482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent self-catheterisation (IMC)
Number of subjects: 207
Study 31953482 — intervention group
Group type: COMPARATOR
Intervention: SPC or IDCs
Number of subjects: 207
Study 30976888 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) with percutaneous kyphoplasty (PKP)
Number of subjects: 101
Study 30976888 — intervention group
Group type: COMPARATOR
Intervention: Control group (calcitriol and calcium carbonate D3 without ZOL)
Number of subjects: 101
Study 28457344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapylin (STG)
Number of subjects: 224
Study 28457344 — intervention group
Group type: EXPERIMENTAL
Intervention: Avitene
Number of subjects: 224
Study 28457344 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 224
Study 26545279 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 2% lidocaine with 1:100,000 epinephrine buffered 9:1 with 8.4% sodium bicarbonate
Number of subjects: 20